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Abstract
Background: Recently a new automatic device that measures brachial-ankle pulse wave velocity
using an oscillometric method has been developed. However, the practical significance of brachial-
ankle pulse wave velocity measurement remains uncertain. The purpose of this study was to
examine the association between brachial-ankle pulse wave velocity and symptomatic cerebral
infarction in patients with type 2 diabetes.
Methods: One thousand sixty six patients with type 2 diabetes were studied cross-sectionally.
Measurements of brachial-ankle pulse wave velocity were made using the automatic device. Logistic
regression analysis was used to calculate the odds ratio for cerebral infarction.
Results: The presence of symptomatic cerebral infarction was confirmed in 86 patients. In these
patients brachial-ankle pulse wave velocity was found to be significantly higher than in patients
without cerebral infarction (18.94 ± 4.95 versus 16.46 ± 3.62 m/s, p < 0.01). The association
between brachial-ankle pulse wave velocity and cerebral infarction remained significant after
adjustment for traditional risk factors. There was an increasing odds ratio for each tertile of
brachial-ankle pulse wave velocity, from the second tertile (odds ratio, 2.28; 95% confidence
interval, 1.05 to 4.94), to the third (odds ratio, 2.53; 95% confidence interval, 1.09 to 5.86).
Conclusion:  Overall, we conclude that an increase in brachial-ankle pulse wave velocity is
associated with symptomatic cerebral infarction in patients with type 2 diabetes.
Background
Pulse wave velocity (PWV) is the velocity of a pulse wave
travelling a given distance between 2 sites in the arterial
system. It has been reported that PWV gives an estimate of
arterial stiffness, and an increase in aortic PWV has been
associated with cardiovascular disease [1–4] Recently, a
new, simple device to measure PWV has been developed.
The device measures brachial-ankle pulse wave velocity
(baPWV) using an oscillometric method. [5] Unlike aortic
PWV, baPWV includes measurements of peripheral artery
velocity. Therefore, the clinical significance of baPWV
may differ from that of aortic PWV. In order to assess the
clinical significance of baPWV measurements, we investi-
Published: 28 August 2003
Cardiovascular Diabetology 2003, 2:10
Received: 23 June 2003
Accepted: 28 August 2003
This article is available from: http://www.cardiab.com/content/2/1/10
© 2003 Ogawa et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/10
Page 2 of 7
(page number not for citation purposes)
gated the association between baPWV and the presence of
symptomatic cerebral infarction in patients with type 2
diabetes.
Methods
Patients with type 2 diabetes who underwent measure-
ment of baPWV between April 2000 and November 2002
at the outpatient department of Juntendo University Hos-
pital (Tokyo, Japan) were enrolled in this study. Informed
consent was obtained from all subjects. Clinical data were
collected cross-sectionally from the medical records. Type
2 diabetes was defined as a fasting plasma glucose concen-
tration of more than 7.0 mmol/L when no treatment was
given, or a plasma glucose concentration of 11.0 mmol/L
or more 2 hours after a 75 g oral glucose load when being
treated with glucose-lowering drugs. Patients selected had
no history of ketoacidosis. Exclusion criteria were an
ankle brachial pressure index (ABI) <0.9, a history of
ischemic heart disease, and a history of atrial fibrillation.
Symptomatic cerebral infarction was defined as a clini-
cally apparent focal or global disturbance of cerebral func-
tion, and was diagnosed by neurological examination and
cranial computer tomography or magnetic resonance
imaging.
Total cholesterol, high-density lipoprotein cholesterol,
triglycerides and hemoglobin A1c were determined using
standard laboratory techniques. Weight and height were
measured in the study subjects whilst they were wearing
light clothing and no shoes. Body mass index (BMI) was
calculated as weight (kilograms)/height (meters) squared.
baPWV, ABI and blood pressure (BP) were measured
using an automatic waveform analyzer (BP-203RPE;
Colin, Komaki, Japan). Measurements were taken with
patients lying in a supine position after 5 minutes of rest
in that position. Occlusion and monitoring cuffs were
placed snugly around both sites of the upper and lower
extremities of patients. Pressure waveforms of the brachial
and tibial arteries were then recorded simultaneously by
an oscillometric method.
Electrocardiogram monitoring was performed with elec-
trodes placed on both wrists. Any arrhythmia recorded
was evaluated. Heart sounds S1 and S2 were detected
using a microphone placed on the left edge of the sternum
at the fourth intercostal space. The pressure waveforms
obtained at 2 different sites were simultaneously recorded
to determine the time interval between the initial rise in
the brachial and tibial pressure waveforms (T). The path
length from the suprasternal notch to the elbow (La) and
the path length from the suprasternal notch to the femur
to the ankle (Lb) were automatically calculated based on
the patient's height and were derived from statistical stud-
ies. baPWV was calculated using the formula baPWV =
(Lb-La)/T. Measurement of right and left baPWV was
obtained for an average of 10 seconds. The reproducibility
of the baPWV measurements was high. In healthy sub-
jects, the interobserver coefficient of variation (CV; n =
15) was 2.4% and the intraobserver CV (n = 17) was 5.8%.
In patients with coronary heart disease, the interobserver
CV (n = 18) was 8.4% and the intraobserver CV (n = 41)
was 13.3%. [5] In 12517 subjects who had no medication
and no history of cardiovascular disease, multiple regres-
Table 1: Characteristics of the 1066 patients enrolled in the study, divided according to the presence (+) or absence (-) of cerebral 
infarction.
Cerebral infarction
(+) n = 86 (-) n = 980 p
baPWV(m/s) 18.94 ± 4.95 16.46 ± 3.62 <0.001
Age (years) 67.3 ± 7.8 60.3 ± 10.7 <0.001
Body mass index (kg/m2) 23.9 ± 2.8 23.9 ± 3.8 0.89
Gender (male/female) 58/28 667/313 0.99
Duration of diabetes (years) 11.3 ± 9.1 9.4 ± 8.7 0.066
Antihypertensive agents (%) 43.0 33.4 0.44
Antihyperlipidemic agents (%) 30.2 22.5 0.14
Systolic blood pressure (mmHg) 137.0 ± 18.5 131.6 ± 19.6 0.014
Diastolic blood pressure (mmHg) 79.2 ± 10.6 78.8 ± 10.8 0.67
Hemoglobin A1c (%) 7.42 ± 1.5 7.56 ± 1.8 0.49
Total cholesterol (mmol/L) 4.95 ± 0.91 5.02 ± 1.06 0.86
HDL-cholesterol (mmol/L) 1.40 ± 0.44 1.47 ± 0.93 0.54
Triglycerides (mmol/L) 1.53 ± 0.83 1.72 ± 1.16 0.82
Smokers (%) 40.7 36.1 0.47
Plus-minus values are means ± S.D. baPWV: brachial ankle pulse wave velocity, HDL: high-density lipoprotein.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/10
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sion analysis demonstrated that age and blood pressure
variables were potent, significant variables for baPWV. [6]
The average of left and right baPWV was used for analysis.
ABI was calculated using the formula ABI=ankle systolic
BP/brachial systolic BP.
Statistical analysis
In order to assess the association between baPWV and cer-
ebral infarction, we performed 2 statistical analyses. In the
first, subjects were divided into 2 groups: those with and
those without cerebral infarction. Clinical characteristics
including baPWV were analyzed in the 2 groups. Contin-
uous variables are given as mean ± SD. We compared con-
tinuous variables using the Student's t-test. We compared
categorical data using the chi-squared test. A probability
value <0.05 was considered statistically significant.
In the second form of analysis, multiple logistic regression
analysis was used to provide an adjusted odds ratio for
cerebral infarction. The variables included in the analysis
were risk factors for cerebral infarction and factors influ-
encing baPWV, including age, gender, BMI, duration of
diabetes, smoking habit, systolic BP, and hyperlipidemia
(defined as serum total cholesterol concentration >5.7
mmol/L, triglyceride concentration >1.7 mmol/L and/or
treatment with antihyperlipidemic agents). The odds ratio
is presented with 95% confidence intervals. Tertiles of the
mean baPWV, age and systolic BP were used for logistic
Frequency distribution of brachial-ankle pulse wave velocity Figure 1
Frequency distribution of brachial-ankle pulse wave velocity. Bar graph showing number of patients with a brachial-ankle pulse 
wave velocity (baPWV) in each range.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/10
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regression analyses. Statistical analyses were performed
using StatView-J 5.0 computer software (SAS Institute Inc.
Cary, NC, USA).
Results
Of 1066 patients eligible to take part in this study, the
presence of symptomatic cerebral infarction was con-
firmed in 86 patients. Table 1 shows the characteristics of
the study group according to the presence or absence of
cerebral infarction. baPWV, age, and systolic BP were sig-
nificantly higher in patients with cerebral infarction than
in those without. The frequency distribution of baPWV is
shown in Figure 1. Scattergrams of age and baPWV in
patients with and without cerebral infarction are shown in
Figures 2 and 3, respectively.
Scattergram of age Figure 2
Scattergram of age. Scattergram showing the ages of patients with and without cerebral infarction.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/10
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The adjusted odds ratios for cerebral infarction are shown
in Table 2. The association between cerebral infarction
and baPWV remained significant after adjustment for age,
gender, diabetes duration, BMI, smoking habit, systolic
BP, and hyperlipidemia. The odds ratios in the second and
third tertiles for patient baPWV were significantly greater
than those in the lowest tertile. The odds ratios in the sec-
ond and third tertiles for patient age were also signifi-
cantly greater than those in the lowest tertile. Systolic BP,
hyperlipidemia and duration were not significantly asso-
ciated with cerebral infarction after adjustment.
Scattergram of brachial-ankle pulse wave velocity Figure 3
Scattergram of brachial-ankle pulse wave velocity. Scattergram showing brachial-ankle pulse wave velocity (baPWV) in patients 
with and without cerebral infarction.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/10
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Discussion
In this study, a high odds ratio for symptomatic cerebral
infarction was associated with a high baPWV value, even
after traditional risk factors for patients with type 2 diabe-
tes had been taken into account. In a previous study, aor-
tic PWV was shown to be associated with cerebrovascular
disease. [1,7] In addition, there was a good correlation
between aortic PWV and baPWV. [5] Our results support
these findings.
Cerebral infarction is commonly considered to be either
atherothrombotic, cardioembolic or lacunar. Cardioem-
bolic infarction occurs together with arrhythmias, espe-
cially atrial fibrillation. [8] We excluded patients with
atrial fibrillation; thus the cause of cerebral infarction in
patients in this study would be expected to be athero-
thrombotic or lacunar in origin. Atherothrombotic infarc-
tion occurs together with atherosclerosis. Therefore, some
patients with symptomatic cerebral infarction in this
study would be expected to show atherosclerotic changes.
In addition, as there was a good correlation between aor-
tic PWV and baPWV, an increase in baPWV may reflect
vascular damage. [5] Aortic PWV has been shown to be
associated with atherosclerosis. [9,10] Therefore, baPWV
is also associated with atherosclerosis.
An advantage of this non-invasive baPWV measurement
method is that it is simple: only a set of cuffs for each limb
is required and patients need not remove any clothing.
Also, the reproducibility of the baPWV measurements
taken was high. [5] Therefore, in clinical practice, meas-
urement of baPWV may be a useful screening test for
atherosclerotic change. The degree of elevation of baPWV
may correspond to the degree of atherosclerotic change: a
very high baPWV may indicate that the atherosclerotic
process is already well established.
The odds ratios of baPWV in second and third tertiles were
similar, and did not increase linearly. This may have been
due to an influence of blood pressure variables on baPWV
[6] Additionally, the use of antihypertensive medication
in patients with cerebral infarction may have decreased
baPWV in this cross-sectional study.
As with any study there were limitations to the present
investigation. For example, since this was a cross-sectional
study, it is unclear from our results whether baPWV is a
predictor for cerebral infarction. However, baPWV is
strongly correlated with aortic PWV, [5] and aortic PWV is
a recognised prognostic predictor [3,11,12] Therefore, it is
possible that baPWV is also a useful predictor. A further
limitation of the present study is that we have only stud-
ied patients with type 2 diabetes, so any associations in
non-diabetic subjects remain to be investigated. In addi-
tion, since measurement of baPWV may be affected by
peripheral conditions such as a lower ABI, caution is
needed when interpreting these results. [13] A further pro-
spective study of the general population would establish
more clearly the clinical significance of baPWV
measurement.
Conclusions
The present study showed that there is an association
between symptomatic cerebral infarction and a high
Table 2: Adjusted odds ratios for cerebral infarction.
No. of subjects No. of events Adjusted odds ratio (95% CI) p
baPWV (m/s) 7.98–14.68 355 10 1.00
14.69–17.73 355 33 2.28 (1.05–4.94) 0.037
17.74–39.57 356 43 2.53 (1.10–5.86) 0.030
Age (years) 23.2–56.9 358 10 1.00
57.0–66.4 363 28 2.52 (1.16–5.46) 0.019
66.5–97.5 345 48 4.59 (2.10–10.06) <0.001
Gender female 341 28 1.00
male 725 58 1.04 (0.60–1.79) 0.90
Body mass index (per kg/m2) 1.04 (0.97–1.12) 0.27
SBP (mmHg) 85–122 356 17 1.00
123–139 372 38 1.64 (0.87–3.10) 0.13
140–219 338 31 1.22 (0.60–2.48) 0.59
Hyperlipidemia no 461 36 1.00
yes 605 50 1.06 (0.66–1.70) 0.80
Duration of diabetes (per year) 1.00 (0.96–1.03) 0.99
Smokers no 677 51 1.00
yes 389 35 1.60 (0.96–2.67) 0.074
baPWV: brachial ankle pulse wave velocity, CI: confidence interval, SBP: systolic blood pressurePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/10
Page 7 of 7
(page number not for citation purposes)
baPWV value in patients with type 2 diabetes. baPWV may
also be a useful marker of atherosclerosis.
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